Inventor · disambiguated record
Tien Lee
Also filed as: LEE TIEN · LEE TIEN-LI
14 granted patents·19 pending applications·71 citations·filing 1999–2025
90Inventor score
Files withAARDVARK THERAPEUTICS INC11NANTKWEST INC9IMMUNITYBIO INC4CELLICS THERAPEUTICS INC2LEE TIEN-LI2
Top patents by PatentIndex Score
33 records- 0197US11207350B2Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancerNANTKWEST INC·Filed 2021·Granted Dec 28, 2021·11 cites·11 claims
- 0297US11000550B2Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancerNANTKWEST INC·Filed 2020·Granted May 11, 2021·6 cites·9 claims
- 0396US10738279B2Modified NK-92 cells for treating cancerNANTKWEST INC·Filed 2016·Granted Aug 11, 2020·16 cites·20 claims
- 0495US12384852B2Genetically modified NK-92 cells having a safety switchIMMUNITYBIO INC·Filed 2021·Granted Aug 12, 2025·2 cites·20 claims
- 0595US10456420B2Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancerNANTKWEST INC·Filed 2016·Granted Oct 29, 2019·19 cites·11 claims
- 0693US10736921B2Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancerNANTKWEST INC·Filed 2019·Granted Aug 11, 2020·5 cites·12 claims
- 0788US2025340664A1Genetically modified nk-92 cell lineIMMUNITYBIO INC·Filed 2025·Application pending·0 cites
- 0879US10835505B2Oral pharmaceutical formulation for weight loss, diabetes and related disordersLEE TIEN LI·Filed 2018·Granted Nov 17, 2020·2 cites·19 claims
- 0978US2024002802A1Modified nk-92 cells for treating cancerIMMUNITYBIO INC·Filed 2023·Application pending·0 cites
- 1069US11788059B2Modified NK-92 cells for treating cancerIMMUNITYBIO INC·Filed 2020·Granted Oct 17, 2023·0 cites·20 claims
- 1169US11110127B2Use of nanoparticles coated with red blood cell membranes to treat hemolytic diseases and disordersCELLICS THERAPEUTICS INC·Filed 2015·Granted Sep 7, 2021·1 cites·16 claims
- 1267US2025049924A1Abuse-Deterrent Pharmaceutical Composition with Aversion PropertiesAARDVARK THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1362US12427125B2Method for treating SARS and treating or preventing ARDSAARDVARK THERAPEUTICS INC·Filed 2021·Granted Sep 30, 2025·0 cites·14 claims
- 1462US2024366505A1Liquid Resin Extended-Release Oral Naltrexone Formulation for Treating Autism-Related DisordersAARDVARK THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1556US12268660B2Oral pharmaceutical formulations of bitter compounds for pulmonary hypertensionAARDVARK THERAPEUTICS INC·Filed 2019·Granted Apr 8, 2025·0 cites·9 claims
- 1654US2023372328A1Oral delayed burst formulation of low-dose naltrexone and methods for treating fibromyalgia and long covidSCILEX HOLDING COMPANY·Filed 2023·Application pending·0 cites
- 1754US2006083697A1Topical skin lightening creamHUYNH ANTHONY V·Filed 2004·Application pending·0 cites
- 1851US2022280457A1Oral pharmaceutical immediate release composition and method of treatment for weight lossAARDVARK THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1950US2024216476A1Combination of bitter receptor agonist and gut-signaling compoundAARDVARK THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2049US2020306302A1Treating and inhibiting leukemia with nk-92 cellsNANTKWEST INC·Filed 2018·Application pending·0 cites
- 2149US2023096528A1Pharmaceutical Composition for Treatment or Prevention of Multiple Inflammatory disordersAARDVARK THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2248US2020171087A1Methods for treating merkel cell carcinoma (mcc) using nk-92 cellsNANTKWEST INC·Filed 2018·Application pending·0 cites
- 2348US2024100001A1Denatonium salt for use in preventing, preventing progression and treating fatty liver diseasesAARDVARK THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2446US2025352498A1Pharmaceutical formulations containing phenylbutyrate and methods thereofAARDVARK THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2545US12201593B2Oral pharmaceutical formulations of bitter compounds for asthmaAARDVARK THERAPEUTICS INC·Filed 2019·Granted Jan 21, 2025·0 cites·12 claims
- 2643US2022193013A1Pharmaceutical Composition for Treatment or Prevention of Multiple Inflammatory DisordersAARDVARK THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2742US2022087960A1Oral Pharmaceutical Immediate Release CompositionZHENG ZHENHUAN·Filed 2020·Application pending·0 cites
- 2842US2020121720A1Nk-92 cells and il-15 agonist combination therapyNANTKWEST INC·Filed 2018·Application pending·0 cites
- 2941US10434070B2Use of nanoparticles coated with red blood cell membranes to enable blood transfusionCELLICS THERAPEUTICS INC·Filed 2015·Granted Oct 8, 2019·0 cites·21 claims
- 3039US2017246209A1Treating viral hemorrhagic fever with nk-92 cellsLEE TIEN·Filed 2015·Application pending·0 cites
- 3137US2017304364A1Nk-92 cells in combination therapy with cancer drugsNANTKWEST INC·Filed 2016·Application pending·0 cites
- 3237US2013224203A1Pharmaceutical Composition of Recombinant Polyclonal ImmunoglobulinsLEE TIEN-LI·Filed 2012·Application pending·0 cites
- 3334US6232113B1Particle bombardment deviceFiled 1999·Granted May 15, 2001·9 cites·8 claims
Join the waitlist — get patent alerts
Get an alert when Tien Lee files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →